The California Institute for Regenerative Medicine (CIRM) Human Pluripotent Stem Cell Biorepository is operated by the Coriell Institute for Medical Research and is a critical component of the CIRM Human Stem Cell Initiative. The overall goal of this initiative is to generate, for world-wide use by non-profit and for-profit entities, high quality, disease-specific induced pluripotent stem cells (iPSCs). These cells are derived from existing tissues such as blood or skin, and are genetically manipulated in the laboratory to change into cells that resemble embryonic stem cells. iPSCs can be grown indefinitely in the Petri dish and have the remarkable capability to be converted into most of the major cell types in the body including neurons, heart cells, and liver cells. This ability makes iPSCs an exceptional resource for disease modeling as well as for drug screening. The expectation is that these cells will be a major benefit to the process for understanding prevalent, genetically complex diseases and in developing innovative therapeutics.
The Coriell CIRM iPSC Biorepository, located at the Buck Institute for Research on Aging in Novato, CA, is funded through a competitive grant award to Coriell from CIRM and is managed by Mr. Matt Self under the supervision of the Program Director, Dr. Steven Madore, Director of Molecular Biology at Coriell. The Biorepository will receive biospecimens consisting of peripheral blood mononuclear cells (PBMCs) and skin biopsies obtained from donors recruited by seven Tissue Collector grant awardees. These biospecimens will serve as the starting material for iPSC derivation by Cellular Dynamics, Inc (CDI). Under a contractual agreement with Coriell, CDI will expand each iPSC line to generate sufficient aliquots of high quality cryopreserved cells for distribution via the Coriell on-line catalogue. Aliquots of frozen cell lines and iPSCs will be stored in liquid nitrogen vapor in storage units at the Buck Institute with back-up aliquots stored in a safe off-site location.
Renovation and construction of the Biorepository began at the Buck Institute in late January. The Biorepository Manger was hired March 1 and after installation of cryogenic storage vessels and alarm validation, the first biospecimens were received on April 30, 2014. Additionally, Coriell has developed a Clinical Information Management System (CIMS) for storing all clinical and demographic data associated with enrolled subjects. Tissue Collectors utilize CIMS via a web interface to upload and edit the subject demographic and clinical information that will ultimately be made available, along with the iPSCs, via Coriell’s on-line catalogue
As of November 1 specimens representing a total of 725 unique individuals have been received at the Biorepository. These samples include PBMCs obtained from 550 unique individuals, skin biopsies from 72 unique individuals, and 103 primary dermal fibroblast cultures previously prepared in the laboratories of the CIRM Tissue Collectors. A total of 280 biospecimen samples have been delivered to CDI for the purpose of iPSC derivation. The Biorepository is anticipating delivery of the first batches of iPSCs for distribution in early 2015. These lines, along with the associated clinical data, will become available to scientists via the on-line Coriell catalogue. The CIRM Coriell iPSC Biorepository will ensure safe long-term storage and distribution of high quality iPSCs.
Reporting Period:
Year 2
The California Institute for Regenerative Medicine (CIRM) Human Pluripotent Stem Cell Biorepository is operated by the Coriell Institute for Medical Research and is a critical component of the CIRM Human Stem Cell Initiative. The overall goal of this initiative is to generate, for world-wide use by non-profit and for-profit entities, high quality, disease-specific induced pluripotent stem cells (iPSCs). These cells are derived from human tissues such as blood or skin, and are genetically manipulated in the laboratory to change into cells that resemble embryonic stem cells. iPSCs can be grown indefinitely in the laboratory and have the remarkable capability to be converted into most of the major cell types in the body including neurons, heart and liver cells, etc. This ability makes iPSCs an exceptional resource for disease modeling as well as for therapy target identification and drug screening. The expectation is that these cells will be a major benefit to the process for understanding prevalent, genetically complex diseases and in developing innovative therapeutics.
The Coriell CIRM hPSC Biorepository, located at the Buck Institute for Research on Aging in Novato, CA, is funded through a competitive grant award to Coriell from CIRM. The Biorepository receives biospecimens consisting of peripheral blood mononuclear cells (PBMCs) and skin biopsies obtained from donors recruited by seven California-based Tissue Collectors funded by CIRM. These biospecimens serve as the starting material for iPSC derivation by Cellular Dynamics, Inc (CDI). Under a contractual agreement with Coriell, CDI expands iPSC clones to generate sufficient aliquots of high quality cryopreserved cells for distribution via Coriell's on-line CIRM Collection Catalog. Aliquots of frozen cell lines and iPSCs are stored in liquid nitrogen vapor in storage units at the Buck Institute with back-up aliquots stored in a Coriell off-site safe storage location.
Coriell has established a Biorepository facility at the Buck Institute and has also developed a Clinical Information Management System (CIMS) for storing all clinical and demographic data associated with enrolled subjects. Tissue Collectors utilize CIMS via a web interface to upload and edit the subject demographic and clinical information that will ultimately be made available, along with the iPSCs, via Coriell’s on-line catalog.
The CIRM hPSC Biorepository released in September 2015 the first 285 iPSCs for distribution. These lines, along with the associated clinical data, are available to scientists via the on-line Coriell catalog. The CIRM hPSC Biorepository will ensure safe long-term storage and distribution of high quality iPSCs and their associated demographic, clinical and genomic data.
Reporting Period:
Year 3
The California Institute for Regenerative Medicine (CIRM) Human Pluripotent Stem Cell Biorepository is operated by the Coriell Institute for Medical Research and is a critical component of the CIRM Human Stem Cell Initiative. The overall goal of this initiative is to generate, for world-wide use by non-profit and for-profit entities, high quality, disease-specific induced pluripotent stem cells (iPSCs). These cells are derived from human tissues such as blood or skin, and are genetically manipulated in the laboratory to change into cells that resemble embryonic stem cells. iPSCs can be grown indefinitely in the laboratory and have the remarkable capability to be converted into most of the major cell types in the body including neurons, heart and liver cells, etc. This ability makes iPSCs an exceptional resource for disease modeling as well as for therapy target identification and drug screening. The expectation is that these cells will be a major benefit to the process for understanding prevalent, genetically complex diseases and in developing innovative therapeutics.
The Coriell CIRM hPSC Biorepository, located at the Buck Institute for Research on Aging in Novato, CA, is funded through a competitive grant award to Coriell from CIRM. The Biorepository receives biospecimens consisting of peripheral blood mononuclear cells (PBMCs) and skin biopsies obtained from donors recruited by seven California-based Tissue Collectors funded by CIRM. These biospecimens serve as the starting material for iPSC derivation by Cellular Dynamics, Inc (CDI). Under a contractual agreement with Coriell, CDI expands iPSC clones to generate sufficient aliquots of high quality cryopreserved cells for distribution via Coriell's on-line CIRM Collection Catalog. Aliquots of frozen cell lines and iPSCs are stored in liquid nitrogen vapor in storage units at the Buck Institute with back-up aliquots stored in a Coriell off-site safe storage location.
Coriell has established a Biorepository facility at the Buck Institute and has also developed a Clinical Information Management System (CIMS) for storing all clinical and demographic data associated with enrolled subjects. Tissue Collectors utilize CIMS via a web interface to upload and edit the subject demographic and clinical information that will ultimately be made available, along with the iPSCs, via Coriell’s on-line catalog.
The CIRM hPSC Biorepository released in September 2015 the first 285 iPSCs for distribution. These lines, along with the associated clinical data, are available to scientists via the on-line Coriell catalog. The CIRM hPSC Biorepository will ensure safe long-term storage and distribution of high quality iPSCs and their associated demographic, clinical and genomic data.
Reporting Period:
Year 4
The CIRM Human Pluripotent Stem Cell Biorepository, operated by the Coriell Institute for Medical Research, is a critical component of the CIRM hPSC Initiative. The goal of the Initiative was to generate high quality disease-specific human pluripotent stem cells. These iPSCs are intented to be used by world-wide non-profit and for-profit entities, for disease modeling and drug discovery and development in prevalent, genetically complex diseases.
As of the end of Year 4, submissions from 2,835 subjects have been received from ten submitting groups and banked at Coriell. To this date, 1,835 P10 Distribution Bank samples and 2,259 P5 Master Bank clones have been generated by Cellular Dynamics International (CDI) and stored at Coriell. At the end of Year 4, 1,547 samples are available for distribution through Coriell’s online catalog. For samples to be available for distribution, clinical data must be completed and reviewed by Coriell staff. The catalog includes Disease specific pages, an Advanced Clinical Data Search, as well as all documents (Material Transfer Agreement and Licensing Agreements) needed to complete an order.
Reporting Period:
Year 5/NCE
The CIRM Human Pluripotent Stem Cell Biorepository, operated by the Coriell Institute for Medical Research until March 2018, was a critical component of the CIRM hPSC Initiative. The goal of the Initiative was to
generate high quality disease-specific human pluripotent stem cells. These iPSCs are intented to be used by world-wide non-profit and for-profit entities, for disease modeling and drug discovery and development in prevalent, genetically complex diseases.
During the first quarter of year 5 (Dec 2017 - March 2018), submissions from 2,838 subjects were received from ten submitting groups and banked at Coriell. To this date, 1,931 P10 Distribution Bank samples and 2,436 P5 Master Bank clones have been generated by FUJIFILM Cellular Dynamics, Inc. and stored at Coriell. The Coriell catalog included Disease Specific pages, an Advanced Clinical Data Search, as well as all documents (Material Transfer Agreement and Licensing Agreements) needed to complete an order. Starting in September 2018, the CIRM iPSC Repository became fully under the management of FUJIFILM Cellular Dynamics, Inc. (FCDI). The collection can now be viewed and ordered thought the FCDI website
Grant Application Details
Application Title:
The CIRM Human Pluripotent Stem Cell Biorepository – A Resource for Safe Storage and Distribution of High Quality iPSCs
Public Abstract:
Critical to the long term success of the CIRM iPSC Initiative of generating and ensuring the availability of high quality disease-specific human IPSC lines is the establishment and successful operation of a biorepository with proven methods for quality control, safe storage and capabilities for worldwide distribution of high quality, highly-characterized iPSCs. Specifically the biorepository will be responsible for receipt, expansion, quality characterization, safe storage and distribution of human pluripotent stem cells generated by the CIRM stem cell initiative. This biobanking resource will ensure the availability of the highest quality hiPSC resources for researchers to use in disease modeling, target discovery and drug discovery and development for prevalent, genetically complex diseases.
Statement of Benefit to California:
The generation of induced pluripotent stem cells (iPSCs) from patients and subsequently, the ability to differentiate these iPSCs into disease-relevant cell types holds great promise in facilitating the “disease-in-a-dish” approach for studying our understanding of the pathological mechanisms of human disease. iPSCs have already proven to be a useful model for several monogenic diseases such as Parkinson’s, Fragile X Syndrome, Schizophrenia, Spinal Muscular Atrophy, and inherited metabolic diseases such as 1-antitrypsin deficiency, familial hypercholesterolemia, and glycogen storage disease. In addition, the differentiated cells obtained from iPSCs represent a renewable, disease-relevant cell model for high-throughput drug screening and toxicology/safety assessment which will ultimately lead to the successful development of new therapeutic agents. iPSCs also hold great hope for advancing the use of live cells as therapies for correcting the physiological manifestations caused by disease or injury.
